PortalPublikationenComplications of Autologous Stem Cell Transplantation in Mul...

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

Standard

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. / Waszczuk-Gajda, Anna; Penack, Olaf; Sbianchi, Giulia; Koster, Linda; Blaise, Didier; Reményi, Péter; Russell, Nigel; Ljungman, Per; Trneny, Marek; Mayer, Jiri; Iacobelli, Simona; Kobbe, Guido; Scheid, Christof; Apperley, Jane; Touzeau, Cyrille; Lenhoff, Stig; Jantunen, Esa; Anagnostopoulos, Achilles; Paris, Laura; Browne, Paul; Thieblemont, Catherine; Schaap, Nicolaas; Sierra, Jorge; Yakoub-Agha, Ibrahim; Garderet, Laurent; Styczynski, Jan; Schoemans, Helene; Moiseev, Ivan; Duarte, Rafael F; Peric, Zinaida; Montoto, Silvia; van Biezen, Anja; Mikulska, Malgorzata; Aljurf, Mahmoud; Ruutu, Tapani; Kröger, Nicolaus; Morris, Curly; Koenecke, Christian; Schoenland, Stefan; Basak, Grzegorz W.

in: J CLIN MED, Jahrgang 11, Nr. 12, 3541, 20.06.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Waszczuk-Gajda, A, Penack, O, Sbianchi, G, Koster, L, Blaise, D, Reményi, P, Russell, N, Ljungman, P, Trneny, M, Mayer, J, Iacobelli, S, Kobbe, G, Scheid, C, Apperley, J, Touzeau, C, Lenhoff, S, Jantunen, E, Anagnostopoulos, A, Paris, L, Browne, P, Thieblemont, C, Schaap, N, Sierra, J, Yakoub-Agha, I, Garderet, L, Styczynski, J, Schoemans, H, Moiseev, I, Duarte, RF, Peric, Z, Montoto, S, van Biezen, A, Mikulska, M, Aljurf, M, Ruutu, T, Kröger, N, Morris, C, Koenecke, C, Schoenland, S & Basak, GW 2022, 'Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study', J CLIN MED, Jg. 11, Nr. 12, 3541. https://doi.org/10.3390/jcm11123541

APA

Waszczuk-Gajda, A., Penack, O., Sbianchi, G., Koster, L., Blaise, D., Reményi, P., Russell, N., Ljungman, P., Trneny, M., Mayer, J., Iacobelli, S., Kobbe, G., Scheid, C., Apperley, J., Touzeau, C., Lenhoff, S., Jantunen, E., Anagnostopoulos, A., Paris, L., ... Basak, G. W. (2022). Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. J CLIN MED, 11(12), [3541]. https://doi.org/10.3390/jcm11123541

Vancouver

Waszczuk-Gajda A, Penack O, Sbianchi G, Koster L, Blaise D, Reményi P et al. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. J CLIN MED. 2022 Jun 20;11(12). 3541. https://doi.org/10.3390/jcm11123541

Bibtex

@article{5caece9b3e2d43329be458d7397396ae,
title = "Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study",
abstract = "Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0−100 days, 101 days−1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4−108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1−7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3−5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.",
author = "Anna Waszczuk-Gajda and Olaf Penack and Giulia Sbianchi and Linda Koster and Didier Blaise and P{\'e}ter Rem{\'e}nyi and Nigel Russell and Per Ljungman and Marek Trneny and Jiri Mayer and Simona Iacobelli and Guido Kobbe and Christof Scheid and Jane Apperley and Cyrille Touzeau and Stig Lenhoff and Esa Jantunen and Achilles Anagnostopoulos and Laura Paris and Paul Browne and Catherine Thieblemont and Nicolaas Schaap and Jorge Sierra and Ibrahim Yakoub-Agha and Laurent Garderet and Jan Styczynski and Helene Schoemans and Ivan Moiseev and Duarte, {Rafael F} and Zinaida Peric and Silvia Montoto and {van Biezen}, Anja and Malgorzata Mikulska and Mahmoud Aljurf and Tapani Ruutu and Nicolaus Kr{\"o}ger and Curly Morris and Christian Koenecke and Stefan Schoenland and Basak, {Grzegorz W}",
year = "2022",
month = jun,
day = "20",
doi = "10.3390/jcm11123541",
language = "English",
volume = "11",
journal = "J CLIN MED",
issn = "2077-0383",
publisher = "MDPI AG",
number = "12",

}

RIS

TY - JOUR

T1 - Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

AU - Waszczuk-Gajda, Anna

AU - Penack, Olaf

AU - Sbianchi, Giulia

AU - Koster, Linda

AU - Blaise, Didier

AU - Reményi, Péter

AU - Russell, Nigel

AU - Ljungman, Per

AU - Trneny, Marek

AU - Mayer, Jiri

AU - Iacobelli, Simona

AU - Kobbe, Guido

AU - Scheid, Christof

AU - Apperley, Jane

AU - Touzeau, Cyrille

AU - Lenhoff, Stig

AU - Jantunen, Esa

AU - Anagnostopoulos, Achilles

AU - Paris, Laura

AU - Browne, Paul

AU - Thieblemont, Catherine

AU - Schaap, Nicolaas

AU - Sierra, Jorge

AU - Yakoub-Agha, Ibrahim

AU - Garderet, Laurent

AU - Styczynski, Jan

AU - Schoemans, Helene

AU - Moiseev, Ivan

AU - Duarte, Rafael F

AU - Peric, Zinaida

AU - Montoto, Silvia

AU - van Biezen, Anja

AU - Mikulska, Malgorzata

AU - Aljurf, Mahmoud

AU - Ruutu, Tapani

AU - Kröger, Nicolaus

AU - Morris, Curly

AU - Koenecke, Christian

AU - Schoenland, Stefan

AU - Basak, Grzegorz W

PY - 2022/6/20

Y1 - 2022/6/20

N2 - Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0−100 days, 101 days−1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4−108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1−7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3−5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.

AB - Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0−100 days, 101 days−1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4−108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1−7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3−5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.

U2 - 10.3390/jcm11123541

DO - 10.3390/jcm11123541

M3 - SCORING: Journal article

C2 - 35743620

VL - 11

JO - J CLIN MED

JF - J CLIN MED

SN - 2077-0383

IS - 12

M1 - 3541

ER -